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a  b  s  t  r  a  c  t
The  chemical  inhibition  of  acetyl-cholinesterase  (AChE)  is a potent  strategy  for addressing
signal  related  neuropathology  and  natural  products  are  potential  sources  of  compounds
with such  properties.  Essential  oil extracts  from  leaf,  seed,  stem  and  rhizome  of four
medicinal  plants  [Aframomum  melegueta  K. Schum,  Crassocephalum  crepidioides  (Benth
S.  More),  Monodora  myristica  (Gaertn.),  and  Ocimum  gratissimum  (Linn)]  were  tested
for  acetyl-cholinesterase  inhibitory  activity  (AChEI)  using  Ellman’s  colorimentric  method
and compared  to  a reference  acetyl-cholinesterase  inhibitor  (galantamine).  The  seed
(IC50 =  6.71  mg/l)  and leaf  (IC50 =  6.54  mg/l)  extracts  from  O.  gratissimum  showed  values  that
matched  the  capacity  of the  reference  inhibitor  (IC50 = 6.62  mg/l).  The  least  potent  extract
was  rhizome  extracts  of  A.  melegueta  (IC50 =  28.97  mg/l)  about  four  times  that  of  the ref-
erence  inhibitor.  Principal  component  analysis  (PCA)  showed  that  the  intrinsic  properties
(bioactive  ingredient  factor)  of each  extract  (PC1  = 29.50%)  was  the  most  important  fac-
tor deﬁning  the difference  or similarity  in  potency  to the  reference  acetyl-cholinesterase
inhibitor  while  ‘dose  response’  (PC2  =  11.38%)  was  the second  most  important  factor.  The
outstanding  AChEI  property  of O.  gratissimum  extracts  could  largely  be  attributed  to  the
high monoterpene  content  while  the  weak  potency  of  rhizome  extracts  of A. melegueta
may  be attributed  to  its predominant  concentrations  of  sesquiterpenes.  Since  potency
could  be related  to interaction  between  bioactive  components,  understanding  the  inter-
action between  ratios  of  monoterpene  and  sesquiterpene  in extracts  could  be important  in
determining  their  potency  for  AChEI.
© 2015  The  Authors.  Published  by Elsevier  Ireland  Ltd.  This  is  an  open  access  article  under
the  CC  BY-NC-ND  license  (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Acetylcholine (ACh) is the principal neurotransmit-
ter which functions in all autonomic ganglia and is the
only neurochemical that triggers motor division of the
somatic nervous system. While normal cholinergic activity
∗ Corresponding author. Tel.: +234 8035426559.
E-mail address: kunleowokotomo@yahoo.com (I.A. Owokotomo).
http://dx.doi.org/10.1016/j.toxrep.2015.05.003
2214-7500/© 2015 The Authors. Published by Elsevier Ireland Ltd. Th
(http://creativecommons.org/licenses/by-nc-nd/4.0/).is deﬁned by the sequence of release, binding and enzy-
matic deactivation of ACh by acetyl-cholinesterase (AChE),
abnormal cholinergic activity on the other hand is charac-
terized by a deﬁcit or short-fall in cholinergic transmissions
at synapses and has been attributed to reduced production
of acetylcholine (ACh) or its excess deactivation/hydrolysis
by AChE [34,47]. The etiologies of cognitive problems high-
light problems with signal transduction across synapses
[32,45] thus regulating the activities of AChE has become
an important research focus [41].
is is an open access article under the CC BY-NC-ND license
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Commercially available synthetic acetyl-cholinesterase
nhibitors (AChEIs) include donepezil (Aricept®), rivastig-
ine (Exelon®), galantamine (Razadyne®), and tacrine
Cognex®) inﬂuence the dynamics of ACh by inhibiting the
ctivity of AChE thus increasing the availability and inter-
ction time of Ach with cholinergic receptors of synaptic
ells. Considering the drawbacks of synthetic AChEIs which
nclude gastrointestinal disturbances, moderate effective-
ess, high cost and short half-life [38,46,49] natural
roduct based compounds have been increasingly explored
or better effects [39,40]. Desirable properties of botani-
al extracts or natural product based compounds include a
omparatively better penetration of the blood–brain bar-
ier better than the pharmaceutical options and better
peciﬁcity for human type AChE (G4) [49]. Although the
nticholinesterase activity of many plant compounds have
een demonstrated, in vitro laboratory trials using essen-
ial oil extracts of tropical plants are very limited.
Plant-derived essential oils exhibit pharmacological
roperties traceable to the presence of various struc-
urally diverse bioactive chemical components [1] and
re increasingly harnessed for their anti-cholinesterase
AChE) properties [33,35,48]. Smail et al. [48] reported the
cetyl-cholinesterase inhibiting potentials of commercial
ssential oils of Citrus aurantium L., Cupressus sempervirens
., and Eucalyptus globulus Labill. Foeniculum vulgare Mill
nd Thymus vulgaris from Morocco. Politeo et al. [44] also
eported high acetyl-cholinesterase inhibition activity of
ssential oil from Pinus nigra Arnold ssp. dalmatica (Vis.)
nd documented -pinene, -pinene, germacrene-d and
-caryophyllene as predominant bioactive compounds.
onsidering the importance of sufﬁcient knowledge base
or accurate recommendations on the use of plant extracts,
his study compares the anti-cholinesterase activity of
ssential oil extracts from four tropical plant species to
alantamine (a commercially available synthetic AChEI).
. Materials and methods
.1. Plant materials and extraction of essential oils
The plant species of medical importance i.e. Aframomum
elegueta (K. Schum), Crassocephalum crepidioides (Benth
. More), Monodora myristica (Gaertn), and Ocimum gratis-
imum (Linn) were harvested at different farm locations in
kure, Ondo State Nigeria. Identiﬁcation was carried out
t the forest research institute Ibadan, Nigeria. Different
lant parts i.e. seed, leaf, stem and rhizome were sepa-
ated washed, cut into small sizes and subjected separately
o hydro-distillation using an all glass Clevenger apparatus
or 3–4 h according to European pharmacopoeia 2008. Oils
ere collected into glass sample bottles and kept in the
efrigerator without further treatment before GC/MS and
cetyl-cholinesterase inhibition analyses.
.2. Gas chromatography/mass spectrometry (GC/MS)The essential oils were analyzed using Agilent (USA)
890N GC Coupled with MS-5973-634071 Series.
he capillary column type was DB-1 (fused-silica)
30.0 m (length) × 320.00 m (diameter) × 1.00 m (ﬁlmeports 2 (2015) 850–857 851
thickness)]. The carrier gas was  Helium at constant ﬂow
rate of 1.0 ml/min and average velocity of 37 cm/s; the
pressure was 0.78 psi. The initial column temperature was
set at 100 ◦C (held for 5 min) to the ﬁnal temperature of
250 ◦C at the rate of 5 ◦C/min. The injector was the split type
and was set at 50:1, and volume injected was  1.0 l. The
chromatograms were auto-integrated by Shem-Station
and the constituents were identiﬁed by comparison of the
GC–MS data with (NIST02) library spectra and data from
literature [2].
2.3. Acetyl-cholinesterase inhibition assay
The acetyl-cholinesterase inhibition assay was  deter-
mined by Ellman colorimetric method [36] as modiﬁed
by Albano et al. [31]. In a total volume of 1 ml,  415 l
of Tris–HCl buffer 0.1 M (pH 8), 10 l of solution of
essential oils in methanol with different concentrations
and 25 l of enzyme (electric eel acetyl-cholinesterase,
type-VI-S, EC 3.1.1.7, Sigma–Aldrich, St. Louis, USA)
solution containing 0.5 U/ml were incubated for 15 min
at room temperature. 75 l of a solution of AChI
(acetyl-thiocholine) (Sigma–Aldrich, Steinheim, Germany)
1.83 mM and 475 l of DTNB (5,5-dithiobis-2-nitrobenzoic
acid), 3 mM (Sigma–Aldrich, Steinheim, Germany) were
added and the ﬁnal mixture incubated for 30 min, at
room temperature. Absorbance of the mixture was mea-
sured at 412 nm in a UV-Visible 752 spectrophotometer
(Techmel and Techmel, USA). Galanthamine hydrobromide
(Sigma–Aldrich, Steinheim, Germany) was used as positive
control. The percentage inhibition of enzyme activity was
calculated by comparison with the negative control:
Inhibition % =
(
A0 − A1
A0
)
× 100
where A0 was  the absorbance of the negative control
(enzyme + methanol) and A1 was the absorbance of the
sample (enzyme + solution of EO). Tests were carried out in
triplicate and data were analyzed using descriptive statis-
tics.
2.4. Estimation of IC50 values
The IC50 values (concentration of test compounds that
inhibits the hydrolysis of substrates by 50%) were deter-
mined by spectrophotometric measurement of the effect
of increasing concentrations of test compounds (plant
extracts and positive controls) on AChE activity. Determi-
nations were carried out in triplicates. To calculate the IC50
values, each sample was  assayed at 5 concentrations (20,
15, 10, 5 and 2.5 mg/ml). IC50 values were obtained from
dose–effect curves by linear regression.
2.5. Inhibition factorThis variable is deﬁned as the inhibitory strength of an
extract relative to the reference inhibitor. The values give
the number of times the essential oil extract is more potent
or less potent than the reference inhibitor.
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Table 1
Summary of acetyl-cholinesterase inhibition by essential oil extracts.
Extract Dose response equation IC10 (mg/l) IC50 (mg/l) IC90 (mg/l) Inhibition factor
(IF) (IC50)
Inhibition factor
(IF) (IC90)
Galatamine (reference) Y = 4.22x + 13.21 ND 6.62 18.22 1 1
O.  gratissimum leaf Y = 3.94x + 24.23 ND 6.54 16.7 1.01 1.09
O.  gratissimum seed Y = 3.65x + 25.53 ND 6.71 17.68 0.99 1.03
C.  crepidiodes leaf Y = 3.64x + 10.14 ND 10.96 21.95 0.6 0.83
A.  melegueta seed Y = 2.53x + 20.31 ND 11.75 27.59 0.56 0.66
C.  crepidiodes stem Y = 4.02x + 1.14 2.2 12.15 22.11 0.55 0.82
M.  myristica seed Y = 2.16x + 17.81 ND 14.9 33.42 0.44 0.55
M.  myristica stem Y = 1.96x + 19.29 ND 15.56 36.13 0.43 0.51
15.27 
16 
28.97 A.  melegueta stem Y = 2.16x + 17.08 ND 
A.  melegueta leaf Y = 2.66x + 7.42 0.97 
A.  melegueta rhizome Y = 1.79x + 1.62 6.52 
It is calculated as
ICx of reference inhibitor
ICx of essential oil extract
where ICx is the concentration of test substance or extract
that inhibited x% of AChE activity.
2.6. Data analysis
Dose relationship plots and dose response equation
were generated using the percentage inhibition of each
extract at each given concentration of each extract. The 10%
(IC10), 50% (IC50) and 90% (IC90) inhibitory concentration
values were calculated from the dose response equation. All
dose response plots and calculations were achieved using
Originlab version 8 (Originlab Corp., USA).
Multivariate statistic i.e. principal component analysis
(PCA) was applied to acetyl-cholinesterase inhibition data
of all extracts to elucidate intricate relationships and pat-
terns of inhibition across essential oil extracts used for this
study. Principal components (PCs) were extracted, percent-
age variance and principal component scores tabulated for
each PC. A PCA biplot created using PC 1 and 2 to graphically
explain similarities or differences in inhibition patterns of
extracts based on the orientation of the variables within
ordination space. PCA was carried out using STATISTICA®
version 7 (Statsoft Inc., USA).
3. Results
3.1. Dose response relationships
The summary of acetyl-cholinesterase inhibition by
essential oil extracts from the different parts of the four
plants used in this study is given in Table 1. The acetyl-
cholinesterase inhibition of each extract was indicated
primarily by its IC50 and complemented by the IC10 and
IC90 as lower and upper limits of their inhibition capacity.
From the IC50, O. gratissimum seed and leaf extracts
showed an AChEI capacity that matched that of the ref-
erence inhibitor galatamine (Table 1). The upper limit of
AChEI by the essential oil extracts as indicated by the
IC90 showed that O. gratissimum seed (17.68 mg/l) and leaf
(16.70 mg/l) extracts gave lower values than the reference
inhibitor (18.22 mg/l). This demonstrates a higher potency
because the essential oil extracts of O. gratissimum were33.82 0.43 0.54
31 0.4 0.59
51.42 0.23 0.35
able to inhibit up to 90% of AChE activity at lower concen-
trations than that of the reference inhibitor.
Essential oil extracts of A. melegueta stem and rhizome
showed the least potency as indicated by their high IC50
and IC90 values (Table 1). A notable feature in the pattern
of AChEI capacity of these essential oil extracts is that the
most potent extracts including the reference inhibitor did
not have a detectable IC10, an indication that their potency
may  not be easily managed to achieve low level inhibitions
when and where necessary. Only essential oil extract from
C. crepidioides stem (2.20 mg/l), A. melegueta leaf (0.97 mg/l)
and A. melegueta rhizome (6.52 mg/l) showed the ability
to achieve a 10% inhibition of AChE (IC10). The lower IC10
value of A. melegueta leaf (0.97 mg/l) showed that it had the
highest potency for low level inhibition.
The inhibition factor of each essential oil extracts
showed that the potency of O. gratissimum extracts where
the IC50 of seed (0.99) and the leaf extracts (1.01) were
approximately equal to that of the reference inhibitor while
they were slightly more potent than galantamine (refer-
ence) at 90% inhibition of AChE. Essential oil extracts of C.
crepidioides leaf [0.83 (83%)] and stem [0.82 (82%)] was  the
next most potent extract achieving up to 80% (0.8) of the
inhibition potential of the reference (galatamine) at 90%
inhibition of AChE (IC90). Extracts from A. melegueta rhi-
zome was  the only extracts that showed less than 50% (0.5)
capacity of the reference inhibitor at IC90.
3.2. Principal component analysis (PCA)
Principal component analysis showed the extraction
of three principal components PC 1, PC 2 and PC 3 each
accounting for 29.50, 11.38 and 6.72% of the variance in
AChE inhibition across essential oil extracts respectively
(Table 2). PC 1 which explains the highest variances rep-
resents the primary factor responsible for the difference in
inhibitory capacity of each essential oil extract.
Viewing the principal component biplot from the PC 1
axis (Fig. 1), the orientation of OC leaf and OC seed along-
side galatamine on the negative axis of PC 1 infers that they
showed similar patterns of AChE inhibition. The orienta-
tion of OC leaf and OC seed farther ahead of galatamine on
the negative axis implies that they achieved more AChE
inhibition than galatamine (the reference inhibitor). The
location of AF rhizome on the positive axis of the PC 1 axis
implies that it showed the least inhibition. The orientation
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Table  2
Principal component scores of variables.
Variables PC 1 (intrinsic factor) PC 2 (dose response factor) PC 3 (not used)
2.5 mg/l 0.92 −0.35 0.02
5.0  mg/l 0.93 −0.32 −0.15
10.0  mg/l 0.95 −0.20 0.14
15.0  mg/l 0.89 0.39 0.03
20.0 mg/l 0.72 0.67 −0.04
Control 0.02 0.03 0.08
Extract {MN seed} 0.09 −0.29 −0.16
Extract {MN stem} 0.10 −0.43 −0.17
Extract {OC seed} −0.45 −0.14 0.48
Extract {OC leaf} −0.49 0.00 0.09
Extract {CR stem} 0.10 0.59 0.48
Extract {AF seed} −0.06 −0.27 −0.04
Extract {AF leaf} 0.24 0.06 0.01
Extract {AF stem} 0.11 −0.32 0.12
Extract {AF rhizome} 0.68 0.09 0.02
Extract {CR leaf} −0.05 0.33 −0.10
A ica.
o
1
a
t
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F
mExtract {galantamine} −0.27 
Variance (%) 29.50 
F, A. melegueta; CR, C. crepidioides; OC, O. gratissimum and MN,  M. myrist
f the exposure concentrations (2.5 mg/l, 5 mg/l, 10 mg/l,
5 mg/l and 20 mg/l) along the positive axis of PC 1 gives
 ﬁrst impression that the orientation of the extracts on
he plots is irrespective of dose used for the study. Thus it
ay  be implied that the orientation of extracts midway of
he PC 1 axis alongside the control shows that the essen-
ial oil of such extracts were impotent if not applied in a
ose-manner. Based on these inferences the PC 1 factor was
ndexed as “intrinsic property” implying that extracts that
howed or did not show AChE inhibition could be traced to
heir intrinsic properties or bioactive ingredients.
From PC 2 axis the separation of lower concentrations
positive axis) from higher concentrations (negative axis)
ives a ﬁrst impression of a dose-response relationship in
ig. 1. Principal component biplot of essential oil extracts based on acetyl-choli
elegueta;  CR, C. crepidioides; OC, O. gratissimum and MN,  M. myristica).0.37 −0.74
11.38 6.72
the distribution of extracts on the biplot. The cluster of
extracts AF seed, AF stem, MN stem and MN  seed on the
negative axis of PC 2 alongside the higher concentrations
implies that these essential oil extracts produce signiﬁ-
cant AChE inhibition only at higher concentrations. The
orientation of CR stem at the furthermost part of the PC
2 axis beyond galatamine and alongside 2.5 mg/l implies
its potency at low concentrations unlike galatamine when
applied in a dose approach.
Table 2 corroborates the depictions of the biplot. For
PC 1 the concurrent positive correlations of the concen-
trations used for the study implies a non-dose relationship
factor operational within that principal component. OC leaf
(−0.49) and OC seed (−0.45) showed the highest negative
nesterase inhibitory capacity observed in the in vitro tests (where AF, A.
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Table 3
Predominant bioactive constituents of essential oil extracts.
Plant species Plant part extract Predominant bioactive constituent Percentage occurrence (%) HYDROCARBON SUBCLASS
A. melegueta
Leaf Myrtenyl acetate 29.06 Monoterpene ester
Limonene 19.45 Monoterpene oleﬁn
-Elemene 8.84 Sesquiterpene
Stem Caryophyllene oxide 19.70 Sesquiterpene
Myrtenyl acetate 14.70 Monoterpene ester
-Eudesmene 10.83 Monoterpene
Seed -Caryophyllene 48.78 Sesquiterpene
-Caryophyllene 32.50 Sesquiterpene
Rhizome Myrtenyl acetate 22.70 Monoterpene ester
Pinocarvyl acetate 11.50 Monoterpene ester
Cyperene 8.96 Sesquiterpene
Caryophyllene 5.97 Sesquiterpene
C.  crepidioides
Leaf -Caryophyllene 10.29 Sesquiterpene
-Cubebene 13.77 Sesquiterpene
Stem Thymol 43.93 Monoterpene phenol
4-Cyclohexabutyramide 20.94 Monoterpene
O.  gratissimum
Leaf -Terpinene 52.86 Monoterpene
Z-tert-butyl-4-hydroxy anisol 13.93 Monoterpene
Caryophyllene 10.37 Sesquiterpene
Seed -Pinene 48.19 Monoterpene
Caryophyllene 10.71 Sesquiterpene
Seed Germocrene-d-4-ol 25.48 SesquiterpeneM.  myristica
Tricycle dec-2-ene 
Stem -Cadinene 
-Elemene 
principal component scores alongside galatamine (−0.27)
implying their similarity in AChE inhibition trend.
AF rhizome had the highest positive principal component
score implying that its inhibitory properties were negative
correlated with that of galatamine (reference inhibitor).
The third principal component was not used for the
study because it accounted for a very low percentage vari-
ance (6.73%) of the total inhibition trends of the essential
oil extracts used in this study.
3.3. Predominant bioactive constituent and AChE
inhibition patterns of essential oil extracts
The major compositions of the essential oils were deter-
mined and reported earlier [42,43,49–53]. The major chem-
ical components of the leaf essential oil of A. melegueta
were identiﬁed as myrtenyl acetate (29.06%), limonene
(19.43%) and -elemene (8.84%). The stem essential oil
contained caryophyllene oxide (19.70%), myrtenyl acetate
(14.70%) and -eudesmene (10.83%). The rhizome essen-
tial oils comprised of myrtenyl acetate (22.70%), pinocarvyl
acetate (11.50%), cyperene (8.96%) and caryophyllene
oxide (5.97%) while the seed volatile oil consisted of
-caryophyllene (48.78%) and -caryophyllene (32.50%).
The most abundant constituents of the leaf essential
oil of C. crepidioides were -caryophyllene (10.29%) and
-cubebene (13.77%) while the dominant constituents
of the stem essential oil were thymol (43.93%) and 4-
cyclohexybutyramide (20.94%). The essential oil of the
leaves of O. gratissimum afforded -terpinene (52.86%), Z-
tert-butyl-4-hydroxy anisole (13.93%) and caryophyllene
(10.37%) while the seeds’ oil yielded -pinene (48.19%)
and caryophyllene (10.71%) as principal components. The
GC/MS analyses of the essential oil of the seeds of6.71 Sesquiterpene
31.31 Sesquiterpene
7.98 Sesquiterpene
M. myristica revealed germacrene-d-4-ol (25.48%), tri-
cycle [5.2.1(1, 5)] dec-2-ene and stem-bark oil yielded
-cadinene (31.31%) and -elemene (17.98%) (6.70%) as
dominant constituents (Table 3).
Also given in Table 3 are the subclasses of the predom-
inant bioactive constituents of the essential oil extracts.
A very notable trend in the predominant bioactive com-
ponents is that essential oils with the higher potency
for inhibiting acetyl-cholinesterase activity had monoter-
penes as their predominant component. The extract of
O. gratissimum seed for instance showed a potency that
exceeded the reference inhibitor (galatamine) (Table 1)
and its predominant bioactive component was  -pinene
(48.19%) (Table 3). Its leaf extract also matched the
potency of the reference inhibitor (Table 1) and had -
terpinene (52.86%) as the major bioactive component
(Table 3). Similarly the next most potent essential oil
extract which produced about 80% of the inhibition capac-
ity of galatamine (Table 1) was  the stem extract of C.
crepidioides which had the monoterpene thymol (43.93%)
as its major bioactive constituent.
Only essential oil extracts of C. crepidioides leaf showed a
high potency and also had sesquiterpenes -caryophyllene
(10.29%) and -cubebene (13.77%) as its predominant
bioactive component. Extracts from M. myristica and A.
melegueta showed moderate to weak AChE inhibition prop-
erties (Table 1) and predominant constituents were either
monoterpene esters or sesquiterpenes (Table 3).
4. DiscussionEssential oils are mixtures of many bioactive com-
pounds whose occurrence are strongly dependent on wide
range of factors ranging from plant species used [3] the
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art of the plant used [4], the season the plant was har-
ested [5], population differences of the same species
6], or even between individuals of the same population
7,8]. Although the bio-inhibitory effect of an essential oil
ould be explained in terms of the individual effects or
oint effects of some main constituents there is still lit-
le knowledge on the nature of interaction between these
ompounds.
The essential oils of A. melegueta generally showed a
eak to moderate potency for inhibiting AChE. The potency
riority for extracts showed seed > leaf > stem > rhizome.
elating this trend to the proﬁle of its predominant bioac-
ive constituents the seed extract was the only one that
ad sesquiterpene in concentrations above 30%. The AChE
nhibition of this extract may  be explained by the high
ontent in sesquiterpenes. A number of studies have
ttributed AChE inhibition to predominant occurrence of
esquiterpenes in extracts [9–11] and synergistic poten-
ial of sesquiterpenes [12]. Patel and Amin [12] although
eported anti-cholinesterase activity in sesquiterpene rich
xtracts of Sphaeranthus indicus ﬂower heads, the individ-
al potency of predominant sesquiterpenes tested negative
hen tested for AChE inhibitory activity. The - and -
aryophyllene constituted the sesquiterpenes with the
ighest occurrence and these have been identiﬁed as low
olecular inhibitors. The low molecular weight feature is
elieved to confer an advantage to this compounds allow-
ng for easy passage across the blood brain barrier [13].
he next potent extract was the leaf which had predom-
nantly monoterpenes and sesquiterpenes in close ratios.
he potency of A. melegueta leaf extracts at low concen-
rations may  be attributed to the presence of limonene
monoterpene) as part of its major constituents. Reports
ave shown that limonene it can act synergistically with
ther terpenes to promote terpene absorption by facili-
ating trans-cellular membrane movement [14]. The weak
otency of essential oil extracts of A. melegueta rhizome
ay  be related to the concurrent occurrence of monoter-
enes and sesquiterpenes in close ratios which may  allow
or antagonistic interactions. Yu et al. [15] reported that the
nti-AChE activity of essential oils is strongly dependent
n the interaction of different terpenoid contents. They
eported different interactions including synergy between
onterpenoids and antagonistic relationships between
onoterpenoids and sesquiterepenes.
Extracts of M.  myristica showed similar moderate
otency for AChE inhibition as observed in majority of the
xtracts of A. melegueta.  Also similarly these extracts were
redominantly concentrated with bicyclic and monocyclic
onoterpenes sesquiterpenes. A possible explanation for
he similarity between the potency of these two groups of
xtracts may  the presence of oxygen containing terpenes
n their essential oils. Reports have shown that the pres-
nce of oxygenated functional groups in bicyclic terpenes
an decrease its capacity to inhibit AChE [16].
The potency of O. gratissimum seed extract which
xceeded the inhibitory capacity of the reference inhibitor
ay  be attributed to its very high -pinene content
48.19%). Pinene is notable for its ability to easily cross
he blood–brain barrier where it inhibits activity of acetyl-
holinesterase, which destroys acetylcholine, resulting ineports 2 (2015) 850–857 855
better memory outcomes. The similar potency exhibited
by O. gratissimum leaf extract may  also be attributed to its
high monoterpene content (terpinene: 52.86%). Miyazawa
et al. [17] estimated the anti-AChE activity of 17 monoter-
penoid compounds (hydrocarbons, alcohols and ketones)
and documented a highest anti-AChE for terpenenes. The
monoterpenes are natural products and main constituents
of essential; they are lipophilic in nature thus allowing their
selective movement into and across membrane structures
[18,19]. The monoterpene -pinene has been demon-
strated as a potent AChE inhibitor [16,20] thus clearly
explaining the potency demonstrated by O. gratissimum
seed extract.
Essential oil extracts of C. crepidioides showed the most
potent AChE inhibition after O. gratissimum. The AChE inhi-
bition pattern of leaf and stem extracts of C. crepidioides
these extracts demonstrates two scenarios of inhibition:
extracts from the leaf had predominant concentrations of
sesquiterpenes i.e. -caryophyllene and -caryophyllene
while the stem extracts had predominant concentrations
of monoterpenes i.e. thymol and 4-cyclohexabutyramide.
This suggests the possibility of synergy between predom-
inant bioactive components in essential oils to cause a
signiﬁcant inhibition in AChE activity irrespective of the
subclass of the active compound. This possibility has also
been documented [15]. Beyond the possibility of synergy
between bioactive components, the potency of monoter-
penes for AChE inhibition has been widely reported. The
potency of monoterpenes has been highlighted on its inter-
actions with cell membrane and their potential to inﬂuence
the ﬂuidity and porosity of membrane structure [21,22] the
antimicrobial action of essential oils have also been linked
to their monoterpenoid components [14,21,23]. Sikkema
et al. [24] showed that, as a result of their lipophilic
character, cyclic monoterpenes will preferentially parti-
tion from an aqueous phase into membrane structures
causing membrane expansion, increased membrane ﬂu-
idity and inhibition of a membrane-embedded enzyme.
In yeast cells and isolated mitochondria, -pinene and
-pinene alter cellular integrity; inhibit respiration and
ion transport processes and increase membrane perme-
ability [14,23]. Other reports on AChE inhibition and high
content of monoterpenes mentioned that 1,8-cineole, cam-
phor, -pinene, -pinene, borneol, linalool, menthone,
carvone, anetole, anisole, have anticholinesterase activity
[10,25–27]. The anticholinergic activity of thymol has been
reported [37] and other studies have suggested that the
potency of thymol and its derivatives thymoquinone and
thymohydroquinone as inhibitors of acetylcholinesterase
(AChE) could be related or linked to its additional antioxi-
dant potential [28].
From the pharmaco-dynamic perspective, the general
patterns of AChE inhibition by essential oil extracts may
be explained on relationship between the structure of the
agonist (bioactive compounds) and receptor sites of AChE
using the principle of drug concentration and effect. The
model assumes that the drug interacts reversibly with its
receptor and produces a maximal effect proportional to the
number of receptors occupied, up to a maximal effect when
all receptors are occupied [29]. In principle this implies that
bioactive components of essential oil elicit AChE inhibition
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when the receptors are fully occupied by the compounds.
Potency describes the relationship between receptor occu-
pancy and the ability to initiate a response at the molecular,
cellular, tissue or system level. Since all extracts showed
50% and 90% inhibition they could all be classiﬁed as being
potent for inhibiting AChE.
A very important disparity in their inhibition potency
is that although most extracts were potent for maximal
effects i.e. IC90, only a few showed potency for minimal
effects (IC10). The potency of essential oil extracts from C.
crepidioides stem and leaf and rhizome of A. melegueta were
detected at low effects. Clinical outcomes have shown that
in cases when patients become tolerant to the effects of
a drug, lowering the dosage or switching drugs are possi-
ble ways of addressing the problem [30]. Thus essential oil
extracts with detectable potency at lower effects may  have
more clinical relevance, but recommendations cannot be
made at this stage of study.
The results also suggest that extracts of O. gratissimum
and C. crepidioides which showed strong AChE properties
similar to galantamine (reference inhibitor) may  be cate-
gorized as high potency agonists because they were able
to elicit inhibition in smaller quantities than the reference
substance. This ability to elicit inhibition at lower concen-
trations may  be interpreted from the concentration–effect
model that they produced maximal response while occu-
pying a relatively low proportion of the total AChE receptor
population. Other extracts particularly i.e. M.  myristica and
A. melegueta could be categorized as low potency agonists
because they required higher concentrations to achieve the
same level of inhibition observed in the high potency ago-
nists.
5. Conclusion
This study has demonstrated different degrees of AChEI
potency for the essential oil extracts, and could be consid-
ered as a ﬁrst level screening stage for these extracts. We
suggest further tests for therapeutic index (dose relation-
ships between desired and undesired effects) and quantal
dose relationships (percentage of individuals producing
quantal effects) to aid clinical decisions and recommenda-
tions.
Furthermore this study has shown or demonstrated the
considerable variability in the composition of the essential
oil from different parts of the same plant. Given this vari-
ability, the overall effect of the essential oil of an aromatic
plant may  not be easily predicted, unless the exact compo-
sition and the type of interactions among its constituents
are known. As such single and mixture inhibition assays
using isolated bioactive compound from potent essen-
tial oils could provide information necessary for desirable
pharmacological outcomes.
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